Melinta Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 290
- Market Cap
- -
- Website
- http://melinta.com
Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02470702
Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02357524
Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post doseDrug: Single-Dose IV Oritavancin Diphosphate and Warfarin
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02340988
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
Pharmacokinetics and Safety of Solithromycin in Adolescents and Children
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT02268279
Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02245243
- Locations
- 🇺🇸
Melinta 112 Study Site, Orlando, Florida, United States
Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea
Phase 3
Completed
- Conditions
- Uncomplicated Urogenital Gonorrhea
- Interventions
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT02210325
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
Phase 3
Completed
- Conditions
- Acute PyelonephritisUrinary Tract Infection Complicated
- Interventions
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 550
- Registration Number
- NCT02166476
Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT02015637
- Locations
- 🇺🇸
Melinta 304 Study, Erie, Pennsylvania, United States
🇺🇸Melinta 304 Study Site, Seattle, Washington, United States
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Phase 3
Completed
- Conditions
- Skin Structures and Soft Tissue InfectionsSkin and Subcutaneous Tissue Bacterial Infections
- Interventions
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 850
- Registration Number
- NCT01984684
- Locations
- 🇨🇳
Melinta 303 Study Site, Zhonghe, Taiwan
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Phase 3
Completed
- Conditions
- Community-acquired Bacterial Pneumonia
- Interventions
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 863
- Registration Number
- NCT01968733